Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

2023
type: Class

Generically Dependent Continuant
type: Class

RDF description of Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir - http://research.umh.es/vivo/pub/articulo/258440
type: Document
rights: termsOfUse
date: 2026-08-01T17:08:03
publisher: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
type: Entity
related by: Autor:109543-Artículo:258440
related by: AutorExt:403470_2023-Artículo:258440
related by: Autor:36736-Artículo:258440
related by: AutorExt:403436_2023-Artículo:258440
ARG_2000028: 258440 vcard
type: Document
related by: AutorExt:403466_2023-Artículo:258440
related by: AutorExt:403474_2023-Artículo:258440
related by: AutorExt:403480_2023-Artículo:258440
related by: AutorExt:403468_2023-Artículo:258440
related by: AutorExt:403471_2023-Artículo:258440
most specific type: Academic Article
page end: 2365
related by: AutorExt:403472_2023-Artículo:258440
included: Medicina Clínica 2023
related by: AutorExt:403481_2023-Artículo:258440
related by: AutorExt:403473_2023-Artículo:258440
related by: AutorExt:403465_2023-Artículo:258440
related by: AutorExt:403467_2023-Artículo:258440
type: Thing
related by: AutorExt:403482_2023-Artículo:258440
type: Article
related by: Autor:35232-Artículo:258440
related by: AutorExt:403438_2023-Artículo:258440
type: Academic Article
related by: AutorExt:403469_2023-Artículo:258440
type: Continuant
related by: AutorExt:403437_2023-Artículo:258440
most specific type: 2023
date time value: 258440 pubdate
related by: AutorExt:403475_2023-Artículo:258440
type: Information Content Entity
type: Anualidad
type: 2023
related by: AutorExt:403479_2023-Artículo:258440
related by: AutorExt:403483_2023-Artículo:258440
page start: 2361
type: Generically Dependent Continuant
has publication venue: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Autor:109543-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403470_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

Autor:36736-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403436_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403466_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403474_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403480_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403468_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403471_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403472_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

Medicina Clínica 2023
type: Anualidad
type: DepartmentReport
type: Thing
type: ResearchReport
type: 2023
includes: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403481_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403473_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403465_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403467_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403482_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

Autor:35232-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403438_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403469_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403437_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403475_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403479_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

AutorExt:403483_2023-Artículo:258440
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
type: Generically Dependent Continuant
type: Journal
type: Thing
type: Collection
type: Entity
publication venue for: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
type: Information Content Entity
type: Periodical
type: Continuant